AOD-9604 (5mg)

Modified C-terminal fragment of human growth hormone (residues 176-191). AOD-9604 is a 16-amino-acid piece of human growth hormone, matching residues 176-191 with an extra tyrosine added to the N-terminus. Researchers at Monash University in Melbourne created it to pull the fat-burning stretch of GH away from the regions that drive growth and insulin effects, which makes it one of the rare research peptides to have come out of Australia.

Adipocyte lipolysis: studies of the beta-3 adrenergic pathway in fat cells. Lipogenesis inhibition: fat-storage endpoints in diet-induced obesity models. Cartilage research: paired with hyaluronic acid in osteoarthritis models. IGF-1 independence: metabolic effects achieved without switching on the growth axis. Rodent studies from the Monash team reported lower fat mass in obese models. Human trials run by Metabolic Pharmaceuticals during the 2000s reported only modest weight loss that fell short of the company's efficacy targets, and obesity development was halted. Work since then has turned to cartilage repair in osteoarthritis models.

Rodent studies reported lower fat mass with no change in food intake. The human obesity trials of the 2000s reported modest weight loss that missed the efficacy targets, which closed that development program; the work since then sits in cartilage models.

The human trials reported tolerability close to placebo, with no effect on glucose or IGF-1, which was exactly the design intent. There is little data at higher doses or over longer durations.

In the published AOD-9604 research, the amounts used were 500 µg/kg body weight, oral, Daily in rat, obese zucker rats (Ng FM et al. (2000)); 0.25 mg intra-articular, alone or with 6 mg hyaluronic acid, Weekly in rabbit, knee osteoarthritis model (Kwon DR et al. (2015)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies AOD-9604 for in-vitro research and does not give dosing guidance for people.

Oral AOD-9604 products do exist, because the fragment is unusually stable and one human study used an oral formulation. Peptide Aus supplies the lyophilised vial, which is the format used in the reconstitution and injection-model research.

One and the same molecule: AOD-9604 is fragment 176-191 with an added tyrosine.

A completely different class: AOD-9604 acts on adipocyte lipolysis, while retatrutide is a receptor agonist that affects appetite and energy expenditure.

That pairing raises growth hormone itself; AOD-9604 is a GH fragment built to sidestep growth-axis effects.

Melbourne is where it was designed and first tested, and its development story is one of the clearest cases of isolating a single region of a hormone from the rest in order to study one effect on its own.

Add about 1 mL of bacteriostatic water slowly down the inside of the vial and swirl gently; do not shake. 5mg in 1 mL gives 5 mg/mL. Refrigerate at 2–8 °C after reconstitution and use within 8–12 weeks. The calculator has this vial preset.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

The Therapeutic Goods Administration (TGA) has not registered AOD-9604 as a medicine in Australia, and it is not approved for human or veterinary use. Peptide Aus provides it as a research reagent for in-vitro laboratory work only. In Australia the supply of any substance for human use falls under the Poisons Standard and the Therapeutic Goods Act, and using the material lawfully is the buyer's responsibility. Anyone after a treatment should consult a doctor.

Directly from Peptide Aus, from Australian stock: AOD-9604 (5mg) is $99.99 AUD including GST. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.